000001695 001__ 1695
000001695 005__ 20180208225327.0
000001695 0247_ $$2pmid$$apmid:19545560
000001695 0247_ $$2DOI$$a10.1016/j.ejphar.2009.06.025
000001695 0247_ $$2WOS$$aWOS:000269933100017
000001695 037__ $$aPreJuSER-1695
000001695 041__ $$aeng
000001695 082__ $$a610
000001695 084__ $$2WoS$$aPharmacology & Pharmacy
000001695 1001_ $$0P:(DE-Juel1)VDB17596$$aSihver, W.$$b0$$uFZJ
000001695 245__ $$aAutoradiographic comparison of in vitro binding characteristics of various tritiated adenosine A2A receptor ligands in rat, mouse and pig brain and first ex vivo results
000001695 260__ $$aAmsterdam$$bElsevier$$c2009
000001695 300__ $$a
000001695 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article
000001695 3367_ $$2DataCite$$aOutput Types/Journal article
000001695 3367_ $$00$$2EndNote$$aJournal Article
000001695 3367_ $$2BibTeX$$aARTICLE
000001695 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000001695 3367_ $$2DRIVER$$aarticle
000001695 440_0 $$021162$$aEuropean Journal of Pharmacology$$v616$$x0926-6917$$y1
000001695 500__ $$aRecord converted from VDB: 12.11.2012
000001695 520__ $$aThe adenosine A(2A) receptor in the basal ganglia is involved in the control of movement and plays a role in movement disorders such as Parkinsonism. Developing ligands to evaluate that receptor by noninvasive methods such as positron emission tomography has a high priority. In vitro radioligand binding guides the selection of ligands for in vivo application. This study measured the binding of the adenosine A(2A) receptor antagonist [(3)H]MSX-2 (3-(3-hydroxypropyl)-8-m-methoxystyryl)-7-methyl-1-propargylxanthine) to rat, mouse and pig brain by autoradiography. Other studies measured binding to membranes from PC12 pheochromocytoma cells. Those binding parameters were compared to those of the adenosine A(2A) receptor antagonist [(3)H]ZM241385 (4-(2-[7-amino-2-(2-furyl)[1,2,4]triazolo[2,3-a][1,3,5]triazin-5-ylamino)ethyl)phenol), the adenosine A(2A) receptor agonist [(3)H]CGS21680 (2-[p-(2-carboxyethyl)-phenethylamino]-5'-N-ethylcarboxamidoadenosine) and the unselective adenosine receptor agonist [(3)H]NECA (5'N-ethylcarboxamido)adenosine). The potency order (K(d)) in the three species was [(3)H]ZM241385<[(3)H]MSX-2<[(3)H]NECA<[(3)H]CGS21680. The density of [(3)H]MSX-2 binding sites was greater in the striatum than in the cortex. Preliminary ex vivo experiments showed that by 10min after iv injection, [(3)H]MSX-2 and [(3)H]CGS21680 crossed the blood-brain barrier to the extent of almost 1% ID/g brain tissue, but [(3)H]NECA and [(3)H]ZM241385 to only 0.2% ID/g. The prior administration of unlabeled ZM241385 significantly lowered brain uptake of [(3)H]MSX-2. In conclusion, [(3)H]MSX-2 has a high affinity and sufficient selectivity for the adenosine A(2A) receptor. It penetrates the blood-brain barrier. Sensitivity to photoisomerization is a limitation. Further investigations assess its suitability as a ligand for imaging the brain adenosine A(2A) receptor.
000001695 536__ $$0G:(DE-Juel1)FUEK409$$2G:(DE-HGF)$$aFunktion und Dysfunktion des Nervensystems$$cP33$$x0
000001695 588__ $$aDataset connected to Web of Science, Pubmed
000001695 650_2 $$2MeSH$$aAdenosine A2 Receptor Agonists
000001695 650_2 $$2MeSH$$aAnimals
000001695 650_2 $$2MeSH$$aAutoradiography
000001695 650_2 $$2MeSH$$aBlood-Brain Barrier: metabolism
000001695 650_2 $$2MeSH$$aBrain: metabolism
000001695 650_2 $$2MeSH$$aCell Membrane: metabolism
000001695 650_2 $$2MeSH$$aChromatography, High Pressure Liquid
000001695 650_2 $$2MeSH$$aFemale
000001695 650_2 $$2MeSH$$aLigands
000001695 650_2 $$2MeSH$$aMice
000001695 650_2 $$2MeSH$$aPC12 Cells
000001695 650_2 $$2MeSH$$aProtein Binding
000001695 650_2 $$2MeSH$$aRats
000001695 650_2 $$2MeSH$$aReceptor, Adenosine A2A: metabolism
000001695 650_2 $$2MeSH$$aSwine
000001695 650_2 $$2MeSH$$aTritium: chemistry
000001695 650_2 $$2MeSH$$aXanthines: chemistry
000001695 650_2 $$2MeSH$$aXanthines: metabolism
000001695 650_7 $$00$$2NLM Chemicals$$aAdenosine A2 Receptor Agonists
000001695 650_7 $$00$$2NLM Chemicals$$aLigands
000001695 650_7 $$00$$2NLM Chemicals$$aMSX 2 compound
000001695 650_7 $$00$$2NLM Chemicals$$aReceptor, Adenosine A2A
000001695 650_7 $$00$$2NLM Chemicals$$aXanthines
000001695 650_7 $$010028-17-8$$2NLM Chemicals$$aTritium
000001695 650_7 $$2WoSType$$aJ
000001695 65320 $$2Author$$aAdenosine A(2A) receptor
000001695 65320 $$2Author$$a[H-3]ZM241385
000001695 65320 $$2Author$$a[H-3]CGS21680
000001695 65320 $$2Author$$a[H-3]MSX-2
000001695 65320 $$2Author$$a[H-3]NECA
000001695 65320 $$2Author$$aBrain imaging
000001695 7001_ $$0P:(DE-Juel1)VDB17597$$aSchulze, A.$$b1$$uFZJ
000001695 7001_ $$0P:(DE-Juel1)VDB12398$$aWutz, W.$$b2$$uFZJ
000001695 7001_ $$0P:(DE-Juel1)VDB59407$$aStüsgen, S.$$b3$$uFZJ
000001695 7001_ $$0P:(DE-HGF)0$$aOlsson, R. A.$$b4
000001695 7001_ $$0P:(DE-Juel1)VDB2513$$aBier, D.$$b5$$uFZJ
000001695 7001_ $$0P:(DE-Juel1)VDB20516$$aHolschbach, M. H.$$b6$$uFZJ
000001695 773__ $$0PERI:(DE-600)2143075-5$$a10.1016/j.ejphar.2009.06.025$$gVol. 616$$q616$$tEuropean journal of pharmacology / Environmental toxicology and pharmacology$$v616$$x0926-6917$$y2009
000001695 8567_ $$uhttp://dx.doi.org/10.1016/j.ejphar.2009.06.025
000001695 909CO $$ooai:juser.fz-juelich.de:1695$$pVDB
000001695 9131_ $$0G:(DE-Juel1)FUEK409$$bGesundheit$$kP33$$lFunktion und Dysfunktion des Nervensystems$$vFunktion und Dysfunktion des Nervensystems$$x0
000001695 9141_ $$y2009
000001695 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000001695 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000001695 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000001695 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000001695 9201_ $$0I:(DE-Juel1)VDB807$$d31.12.2008$$gINB$$kINB-4$$lNuklearchemie$$x0
000001695 970__ $$aVDB:(DE-Juel1)103268
000001695 980__ $$aVDB
000001695 980__ $$aConvertedRecord
000001695 980__ $$ajournal
000001695 980__ $$aI:(DE-Juel1)INM-5-20090406
000001695 980__ $$aUNRESTRICTED
000001695 981__ $$aI:(DE-Juel1)INM-5-20090406